G1 Therapeutics

196 articles with G1 Therapeutics

• G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

  3/1/2023

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2022.

• G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

  2/28/2023

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on March 7th, 2023, at 10:30 AM EST, G1’s Chief Executive Officer Jack Bailey will participate in the moderated Breast and Lung Cancer Panel during the Cowen 43rd Annual Health Care Conference.

• G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023

  2/22/2023

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2022 on Wednesday, March 1, 2023, at 8:30 a.m. ET.

• G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

  2/13/2023

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced topline results from its pivotal Phase 3 PRESERVE 1 trial showing that the trial achieved its co-primary endpoints related to severe neutropenia with statistical significance; however, early anti-tumor efficacy data, including overall response rate (ORR) and preliminary measures of survival, favored the placebo arm.

• First Prescription for COSELA® (trilaciclib) Issued in China

  2/9/2023

  Simcere Pharmaceutical Group Limited announce a significant milestone in the fight against cancer with the issuance of the first prescription for COSELA® (trilaciclib) in China.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2023

  2/1/2023

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 2,800 shares of G1’s common stock and 1,400 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference

  1/11/2023

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the virtual 2023 B. Riley Securities 3rd Annual Oncology Conference.

• G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

  1/9/2023

  G1 Therapeutics, Inc. (Nasdaq: GTHX) today announced the 2023 data readouts that are expected to drive its near-term and long-term indications and potential future treatment paradigms for some of the most aggressive and refractory cancers, including metastatic colorectal (mCRC), bladder or urothelial cancer (mUC), and triple negative breast cancer (TNBC).

• G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023

  1/4/2023

  G1 Therapeutics, Inc. today provided an initial update on PRESERVE 3, an ongoing Phase 2, randomized, open-label study of first-line platinum-based chemotherapy and maintenance therapy with the immune checkpoint inhibitor, avelumab, administered alone, or in combination with trilaciclib, in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC).

• G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference

  1/3/2023

  G1 Therapeutics, Inc. announced that on January 11, 2023, at 1:30 PM PST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 41st Annual J.P. Morgan Healthcare Conference.

• Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment

  12/7/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2 mechanism of action (MOA) trial showing favorable alterations in the tumor microenvironment from a single dose of trilaciclib monotherapy as measured by increases in the proportions of CD8+ T cells compared to T regulatory cells (Tregs) in patients with early-stage triple negative breast cancer (TNBC).

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022

  12/2/2022

  G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 14,400 shares of G1’s common stock and 9,400 restricted stock units to five hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference

  11/23/2022

  G1 Therapeutics, Inc. today announced that Jack Bailey, G1’s Chief Executive Officer, and other members of the executive team will participate virtually in the Evercore ISI HealthCONx Conference. The fireside chat with G1 will be held at 1:25PM EST on November 30, 2022.

• G1 Therapeutics Announces Closing of Offering of Common Stock

  11/22/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share.

• G1 Therapeutics Announces Pricing of Offering of Common Stock - November 18, 2022

  11/18/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the pricing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share, for total gross proceeds of $50,050,000.

• G1 Therapeutics Announces Proposed Public Offering of Common Stock - November 17, 2022

  11/17/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced that it has commenced an underwritten public offering of its common stock.

• Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)

  11/2/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, described safety data from the first 18 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate, sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer.

• G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights

  11/2/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the third quarter ended September 30, 2022.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2022

  11/1/2022

  G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 5,200 shares of G1’s common stock and 3,400 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer

  10/26/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it is supporting a Phase 2 investigator initiated study (ISS) of trilaciclib and lurbinectedin in patients with extensive stage small cell lung cancer (ES-SCLC).